 Connection
Michael Mitchell to Cancer Vaccines
This is a "connection" page, showing publications Michael Mitchell has written about Cancer Vaccines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.564 |
|
|
|
-
Zeng Y, Xu J, Wang J, Xue L, Liu J, Geisler HC, Ma X, Melamed JR, Shi Q, Padilla MS, Luo Z, Zhu J, Thatte AS, Figueroa-Espada CG, Ang MJY, Murray AM, Yamagata HM, Kim D, Metzloff AE, Weissman D, Mitchell MJ. mRNA lipid nanoparticle cancer vaccine platform delivering multiple STING activators for enhanced antitumor activity. Proc Natl Acad Sci U S A. 2026 Jul 14; 123(28):e2525718123.
Score: 0.877
-
Gong N, Alameh MG, El-Mayta R, Xue L, Weissman D, Mitchell MJ. Enhancing in situ cancer vaccines using delivery technologies. Nat Rev Drug Discov. 2024 08; 23(8):607-625.
Score: 0.763
-
Zhang R, Billingsley MM, Mitchell MJ. Biomaterials for vaccine-based cancer immunotherapy. J Control Release. 2018 12 28; 292:256-276.
Score: 0.513
-
Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021 01; 16(1):25-36.
Score: 0.150
-
Gong N, Zhang Y, Teng X, Wang Y, Huo S, Qing G, Ni Q, Li X, Wang J, Ye X, Zhang T, Chen S, Wang Y, Yu J, Wang PC, Gan Y, Zhang J, Mitchell MJ, Li J, Liang XJ. Proton-driven transformable nanovaccine for cancer immunotherapy. Nat Nanotechnol. 2020 12; 15(12):1053-1064.
Score: 0.148
-
Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 03 08; 17(3):1326-1335.
Score: 0.113
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|